Moleculin Biotech Q2 EPS $(0.20) Beats $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech reported Q2 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.28) by 28.57%. This is a 16.67% increase over losses from the same period last year. The company had cash and cash equivalents of $32.2 million as of June 30, 2023.
August 11, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin Biotech reported better than expected Q2 losses, which could positively impact the stock in the short term.
Moleculin Biotech reported a smaller loss than expected, which is generally seen as positive news by investors. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100